Patients in the US with epidermal growth factor receptor mutated (EGFRm) advanced lung cancer can now receive an important new treatment option delaying disease progression by nearly nine additional months.
dsm-firmenich, today (February 15) announces its exclusive partnership with Zerion Pharma A/S to unlock a new era in cannabinoid innovation that champions patient-centric formulations.
OM1 says it wants to stand at the helm of a healthcare revolution, fostering an integrated approach to generating and utilizing real-world evidence (RWE), reshaping the foundation of healthcare.
Inceptua Group and Cycle Pharmaceuticals partnership will give access to Free Goods Partnership that gets medicine to patients with extremely rare genetic conditions, which they would be unable to access otherwise.
Pharma giant, GSK, plans to invest £200 million ($253 million) into the UK over the next two years and has acquired Aiolos Bio for $1.1 billion (£870 million).
It is five years this month since a ground-breaking change in UK healthcare history happened – with doctors being able to prescribe cannabis-based medicines for the first time.
Vice president and global head of bioanalytical and central lab services, Lan Li has always found doctors fascinating. Their ability to save lives and give second chances set her on her career path, but it was recognizing there were still so many unmet...
M&G Investments has made a $57 million investment with Swiss-based tech firm, SkyCell and says it is seeking to change the face of international pharma supply chains.
The world’s first anti-fibrotic small molecule inhibitor, discovered and designed by generative artificial intelligence (AI) has completed the first patient dose in a phase 2 clinical trial.
Coordinating with Migraine and Headache Awareness Month (MHAM), this June, Pfizer has announced it is partnering with multi-award winning, singer and actress, Lady Gaga, who was diagnosed with migraine when she was 14.
Global Healthcare Opportunities (GHO) Capital Partners LLP along with Partners Group has announced today (May 25) that it has invested an undisclosed amount in GHO portfolio company, Sterling Pharma Solutions.
Kadam Exports Private has received a statement of non-compliance with GMP after the Danish Medicines Agency found manufacturing deficiencies at its facility in Gujarat.
Medidata and Syapse have teamed up to develop a new suite of solutions, which will aim address precision medicine challenges and accelerate clinical research in oncology for trial sponsors.
Metrion Biosciences has acquired a portfolio of more than 2,000 small molecule potassium channel inhibitors from Japan Tobacco Inc. (JT), with potential application in a variety of clinical indications.
Weill Cornell Medicine has joined TriNetX’s global health research network, enabling it to collaborate with researchers and attract clinical trial opportunities.
Radiopharmaceuticals firm Telix Pharmaceuticals Limited has established a subsidiary in Japan to support clinical development and manufacturing activities.
PRA Health Sciences has opened a new clinic in Salt Lake City, which will offer full-service early stage clinical research capabilities for healthy participants and specialized patient populations.
McKesson Corporation has completed its acquisition of RxCrossroads to support customer needs beyond channel distribution as the industry faces increasing challenges.
The Patient Engagement Collaborative will include 16 patients, caregivers, and patient group representatives who will provide “a collective, all-encompassing patient voice,” says CTTI project manager.
Brammer Bio has completed renovations at its gene therapy manufacturing facility in Cambridge, MA amid industrywide capacity concerns as more biologics enter late-stage clinical trials.
AmerisourceBergen Corporation will buy US wholesaler H.D. Smith, which it says will boost capabilities and help secure the pharmaceutical supply chain.
The Danish Medicines Agency (DKMA) has banned Europharma from performing manufacturing activities citing a general lack of will and ability to adhere to GMP.
The Tri-Institutional Therapeutics Discovery Institute, Inc. will use ChemDiv's proprietary discovery chemistry platform to advance its research and development (R&D) pipeline.
Sotera Health – the recently rebranded Sterigenics International – will add extractables and leachables testing services to its Nelson Labs business with the acquisition of Toxikon Europe NV.
The acquisition of FMC Corporation's health and nutrition business gives DowDuPont “one of the broadest pharma offerings to serve the growing excipients industry,” the firm says.
The National Institute of Health (NIH) has awarded Pharmaceutical Product Development, LLC (PPD) a seven-year contract for clinical research support services.
Clinigen Group plc has acquired the Japanese unlicensed medicines supplier International Medical Management Corporation (IMMC) in order to further develop its market access, says CEO.
Researchers are creating a “roadmap” for nephrology clinical trial design, which stresses the role patients and their families can play in rare disease study design.
The new Princeton, NJ-based office is the result of a multimillion-dollar investment and continued growth driven by an increasing use of medical imaging in clinical research.
Rare disease therapies need to be administered in a way that suit the patient according to Shire CEO Flemming Ørnskov, who says smart, flexible delivery devices are core to the firm's product development strategy.
This month’s roundup features LabCorp newly created enterprise-wide chief medical officer position and two new hires at WIRB-Copernicus Group’s eCOA arm.
Parexel's alliance with the Osaka International Cancer Institute focuses on supporting efficient patient recruitment and advancing new cancer treatments.
The combined offering leverages Elligo’s infrastructure and services to enable Allscripts physicians to participate as study investigators in contract research organization-managed (CRO) clinical trials.
BioreclamationIVT has acquired the biospecimen and research services provider, Asterand Bioscience, following the purchase of TransCell Science earlier this year.
